CD90/THY1 is over-expressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker

Journal Article · Fri Oct 01 00:00:00 EDT 2010 · Modern Pathology, 23(10):1346-1356

DOI:https://doi.org/10.1038/modpathol.2010.122· OSTI ID:1000618

True, Lawrence D; Zhang, Hui; Ye, Mingliang; Huang, Chung-Ying; Nelson, Peter S; Von Haller, Priska D; Tjoelker, Larry W; Kim, Jong Seo; Qian, Weijun; Smith, Richard D; Ellis, William J; Liebeskind, Emily S; Liu, Alvin Y

A by-product in the processing of prostate tissue for cell sorting by collagenase digestion is the media supernatant that remains after the cells are harvested. These supernatants contain proteins made by the cells within the tissue. Quantitative proteomic analysis of Nglycosylated proteins detected an increased amount of CD90/THY1 in cancer supernatants compared to non-cancer supernatants. Immunohistochemistry showed that in all carcinomas, regardless of Gleason grade, a layer of CD90-positive stromal fibroblastic cells, approximately 5-to-10 cells deep, was localized to tumor glands. In contrast, a no more than 1-cell wide girth of CD90-positive stromal cells was found around benign glands. The increased number of CD90-positive stromal cells in cancer correlated with overexpression of CD90 mRNA detected by gene expression analysis of stromal cells obtained by laser-capture microdissection. There is increasing evidence that cancer-associated stroma plays a role in both tumor progression and carcinogenesis. Most experiments to identify cancer biomarkers have focused on the cancer cells. CD90, being a marker for prostate cancer-associated stroma, might be a potential biomarker for this cancer. A non-invasive test could be provided by a urine test. Proteomic analysis of urine from patients with prostate cancer identified CD90; conversely, CD90 was not detected in the urine of post-prostatectomy patients. Furthermore, this urinary CD90 protein was a variant CD90 protein not known to be expressed by such cells as lymphocytes that express CD90. These CD90 results were obtained from ~90 cases consisting of proteomic analysis of tissue and urine, immunohistochemistry, Western blot analysis of tissue media, flow cytometry of cells from digested tissue, and reverse transcriptase polymerase chain reaction analysis of isolated stromal cells.

• Research Organization: Pacific Northwest National Lab. (PNNL), Richland, WA (United States). Environmental Molecular Sciences Lab. (EMSL)
• Sponsoring Organization: USDOE
• DOE Contract Number: AC05-76RL01830
• OSTI ID: 1000618
• Report Number(s): PNNL-SA-74146; ISSN 1530--0285; 24698; 400412000; TRN: US201101%%418
• Journal Information: Modern Pathology, 23(10):1346-1356, Vol. 23, Issue 10; ISSN 0893--3952
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
99 GENERAL AND MISCELLANEOUS//MATHEMATICS, COMPUTING, AND INFORMATION SCIENCE
BY-PRODUCTS
CARCINOGENESIS
CARCINOMAS
DIGESTION
FIBROBLASTS
GENES
GLANDS
LYMPHOCYTES
NEOPLASMS
PATIENTS
POLYMERASE CHAIN REACTION
PROCESSING
PROSTATE
PROTEINS
SORTING
URINE
cancer
CD90 variant
glycoproteins
prostate
proteomics
stroma
urine analysis TANDEM MASS-SPECTROMETRY
CELL-SURFACE MOLECULES
AFFINITY TAG ICAT
THY-1 EXPRESSION
CD40 EXPRESSION
SOFTWARE TOOLS
STROMAL CELLS
GENE
TRANSCRIPTOMES
Environmental Molecular Sciences Laboratory